These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26355873)

  • 1. The Role of MicroRNA in Hepatitis C Virus Replication.
    Duan XQ; Li SL; Li YJ; Liu B; Zeng PB; Yang CH; Chen LM
    J Clin Transl Hepatol; 2013 Dec; 1(2):125-30. PubMed ID: 26355873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-130a inhibits HCV replication by restoring the innate immune response.
    Li S; Duan X; Li Y; Liu B; McGilvray I; Chen L
    J Viral Hepat; 2014 Feb; 21(2):121-8. PubMed ID: 24383925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-135a Modulates Hepatitis C Virus Genome Replication through Downregulation of Host Antiviral Factors.
    Sodroski C; Lowey B; Hertz L; Jake Liang T; Li Q
    Virol Sin; 2019 Apr; 34(2):197-210. PubMed ID: 30456659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.
    Mukherjee A; Di Bisceglie AM; Ray RB
    J Virol; 2015 Mar; 89(6):3356-65. PubMed ID: 25589644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host.
    Thibault PA; Wilson JA
    Pharmacol Res; 2013 Sep; 75():48-59. PubMed ID: 23541631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection.
    Lee CH; Kim JH; Lee SW
    Curr Drug Targets; 2017; 18(7):756-765. PubMed ID: 27033188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection.
    Qian X; Xu C; Fang S; Zhao P; Wang Y; Liu H; Yuan W; Qi Z
    Stem Cells Transl Med; 2016 Sep; 5(9):1190-203. PubMed ID: 27496568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J
    Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
    Kapol N; Lochid-Amnuay S; Teerawattananon Y
    BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs: Role in Hepatitis C Virus pathogenesis.
    Shrivastava S; Steele R; Ray R; Ray RB
    Genes Dis; 2015 Mar; 2(1):35-45. PubMed ID: 25984557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus infection, microRNA and liver disease progression.
    Shrivastava S; Mukherjee A; Ray RB
    World J Hepatol; 2013 Sep; 5(9):479-86. PubMed ID: 24073299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection.
    Wong MT; Chen SS
    Cell Mol Immunol; 2016 Jan; 13(1):11-35. PubMed ID: 25544499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus: molecular biology & current therapeutic options.
    Sharma SD
    Indian J Med Res; 2010 Jan; 131():17-34. PubMed ID: 20167971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.
    Chou WW; Huang CF; Yeh ML; Tsai YS; Hsieh MY; Huang CI; Huang JF; Tsai PC; Hsi E; Juo SH; Tsai WL; Chuang WL; Yu ML; Dai CY
    J Mol Med (Berl); 2016 Mar; 94(3):311-20. PubMed ID: 26489607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
    Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
    Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. microRNAs: novel players in hepatitis C virus infection.
    Li X; Yang W; Ye W; Jin L; He J; Lou L
    Clin Res Hepatol Gastroenterol; 2014 Dec; 38(6):664-75. PubMed ID: 24875730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management issues in chronic viral hepatitis: hepatitis C.
    Sievert W
    J Gastroenterol Hepatol; 2002 Apr; 17(4):415-22. PubMed ID: 11982722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
    Lin TY; Yeh ML; Huang CI; Chen YL; Dai CY; Huang JF; Lin ZY; Chen SC; Huang CF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2017 Jun; 33(6):284-289. PubMed ID: 28601232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.